about
Modulation of antioxidant enzymatic activities by certain antiepileptic drugs (valproic acid, oxcarbazepine, and topiramate): evidence in humans and experimental modelsTherapeutic Drug Monitoring of the Newer Anti-Epilepsy MedicationsPopulation pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.Oxcarbazepine in bipolar disorder: a critical review of the literature.Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring.The pharmacology of bipolar disorder during pregnancy and breastfeeding.Simultaneous UPLC-MS/MS determination of antiepileptic agents for dose adjustment.Development and validation of a reversed-phase HPLC method for licarbazepine monitoring in serum of patients under oxcarbazepine treatment.Oxcarbazepine in the treatment of bipolar disorder: a review.Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin.Oxcarbazepine in neuropathic pain.Treatment and management of epilepsy in the elderly demented patient.Overnight transition from carbamazepine to oxcarbazepine in children and adolescents.The HLA-A*31:01 allele: influence on carbamazepine treatmentDrug interactions involving the new second- and third-generation antiepileptic drugs.Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications.Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects.Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells.Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature.Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.The onset of acute oxcarbazepine toxicity related to prescription of clarithromycin in a child with refractory epilepsy.Acute oxcarbazepine overdose in an autistic boy.Effect of oral contraceptives on lamotrigine levels depends on comedication.Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study.Measurement of 10,11-dihydro-10-hydroxy-carbamazepine in serum and plasma by high-performance liquid chromatography.Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food.Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases.Oxcarbazepine use in essential tremor.Pain Management in Pediatric Chronic Kidney Disease.
P2860
Q27010741-3D221129-928E-4878-8CDA-26DA77592B9BQ33996679-7BA3A276-4A87-472F-9F9D-7E6995A49997Q34295058-DC09D625-BFAB-41A4-9E14-0A0F7E5D26B3Q34610837-64633124-CE66-4F3D-A06D-5163F8B6E932Q35014028-953932AE-056E-4B75-ABEF-BAF932E54230Q35779335-84D48DA6-8662-4A9C-9BDE-FF7B571B0EC6Q36225438-C365BBE9-F027-48C5-BE5C-F4A8B2874A34Q36275095-2D237196-764C-42B6-8550-7A260B45E48BQ36577870-3E424639-CD42-4146-ABA1-348B8DA8F324Q36762432-0B25444E-218C-4A96-8014-48AE2629BEEAQ36964709-01790A36-BD6E-466F-B1E1-AB70A2234B98Q37178698-9F7A84E3-D283-4654-8AA2-EA7F022E54AEQ37281567-D25040C3-E872-4497-A7F3-978116CB31DEQ37626751-592716FB-CDCA-4E7C-9C78-4A7C4530CFA5Q37658910-DC3B566B-40C3-4DF2-89C3-3632EB72104BQ38077586-5CF7C1AA-9EDD-4735-B186-81B407F7C60DQ38152329-D15756FA-D445-47EB-B166-3B7B6F35D9DFQ38586750-842C7C67-40A6-4DD1-80A2-C557799E32E6Q38644163-289154D7-1FBE-458F-B9DB-FB2EC891A2D5Q38808413-D8010AD9-CC54-4DA2-9D57-5D60D4004A70Q38944443-7A8DE58A-2182-4572-BA20-059F3B0160D4Q41380075-E966CE1D-B060-4692-81F5-F471F3CD133CQ42905452-CC7C6D8A-7DDB-4721-91C0-F2ECB8F56857Q43122951-D2ECB0E9-50FA-4E38-9890-587078128A0BQ44458123-24E225DF-5EC6-4E87-BA30-07D6F65BF00BQ45172659-E74A1B69-2B91-450A-B8A5-997FA1B797B0Q46401241-0E060742-E674-4B34-9AFC-02293CC2451AQ46624949-7E1D79DF-5052-4CE4-9581-E8CED106B1DDQ46765555-DD2078CB-B66E-4CB2-8E83-546F00D0CF54Q46984904-724F9487-FB0A-4E82-B510-47BB5B2D09BDQ48214354-8A953333-3C79-482A-A737-A67E4B2C77C5Q50278024-20448AA9-173E-4547-AEE9-D1A7462E8B6CQ55405502-23AF18A1-D06B-4061-8B51-6F9EF7E51ACD
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Clinical pharmacokinetics of oxcarbazepine.
@ast
Clinical pharmacokinetics of oxcarbazepine.
@en
type
label
Clinical pharmacokinetics of oxcarbazepine.
@ast
Clinical pharmacokinetics of oxcarbazepine.
@en
prefLabel
Clinical pharmacokinetics of oxcarbazepine.
@ast
Clinical pharmacokinetics of oxcarbazepine.
@en
P2093
P1476
Clinical pharmacokinetics of oxcarbazepine.
@en
P2093
Bernhard Rambeck
Elisabeth Korn-Merker
Theodor W May
P304
P356
10.2165/00003088-200342120-00002
P577
2003-01-01T00:00:00Z
P6179
1028106517